These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11583352)

  • 1. Intravesical oxybutynin affects bladder permeability.
    Ersay A; Demirtas OC
    Int Urol Nephrol; 2001; 32(3):359-61. PubMed ID: 11583352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histologic studies of intravesical oxybutynin in the rabbit.
    Landau EH; Fung LC; Thorner PS; Mittelman MW; Jayanthi VR; Churchill BM; McLorie GA; Steckler RE; Khoury AE
    J Urol; 1995 Jun; 153(6):2022-4. PubMed ID: 7752387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urodynamic effects of intravesical oxybutynin chloride in conscious rats.
    Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M
    J Urol; 1996 Feb; 155(2):768-71. PubMed ID: 8558722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical effect of intravesical oxybutynin.
    Bonney WW; Robinson RA; Theobald RJ
    J Urol; 1993 Nov; 150(5 Pt 1):1522-5. PubMed ID: 8411446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical oxybutynin: a local anesthetic effect on bladder C afferents.
    De Wachter S; Wyndaele JJ
    J Urol; 2003 May; 169(5):1892-5. PubMed ID: 12686868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathologic and Urodynamic Effects of the Anticholinergic Drugs Oxybutynin, Tolterodine, and Trospium on the Bladder.
    Orgen S; Deliktas H; Sahin H; Gedik A; Nergis Y
    Low Urin Tract Symptoms; 2017 Jan; 9(1):52-56. PubMed ID: 28120444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
    Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
    Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating detrusor muscle concentrations of oxybutynin after intravesical delivery in an ex vivo porcine model.
    Williams NA; Lee KM; Allender CJ; Bowen JL; Gumbleton M; Harrah T; Raja A; Joshi HB
    J Pharm Sci; 2015 Jul; 104(7):2233-40. PubMed ID: 25989054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder.
    Oki T; Kimura R; Saito M; Miyagawa I; Yamada S
    J Urol; 2004 Nov; 172(5 Pt 1):2059-64. PubMed ID: 15540789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective action of intravesical oxybutynin on bladder ultrastructure in rabbits with detrusor overactivity.
    Yamamoto H; Kawano PR; Balasteghin KT; Padovani CR; Amaro JL
    Int Urogynecol J Pelvic Floor Dysfunct; 2009 Feb; 20(2):229-34. PubMed ID: 18953475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
    Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
    Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.
    Krause P; Fuhr U; Schnitker J; Albrecht U; Stein R; Rubenwolf P
    J Urol; 2013 Nov; 190(5):1791-7. PubMed ID: 23669567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder permeability in interstitial cystitis is similar to that of normal volunteers: direct measurement by transvesical absorption of 99mtechnetium-diethylenetriaminepentaacetic acid.
    Chelsky MJ; Rosen SI; Knight LC; Maurer AH; Hanno PM; Ruggieri MR
    J Urol; 1994 Feb; 151(2):346-9. PubMed ID: 8283521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
    Ikeda K; Kobayashi S; Suzuki M; Miyata K; Takeuchi M; Yamada T; Honda K
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):97-103. PubMed ID: 12122494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of intravesical oxybutynin on the ice water test and on electrical perception thresholds in patients with neurogenic detrusor overactivity.
    Van Meel TD; De Wachter S; Wyndaele JJ
    Neurourol Urodyn; 2010 Mar; 29(3):391-4. PubMed ID: 19787712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of oxybutynin on structural changes of the obstructed guinea pig bladder.
    Scheepe JR; de Jong BW; Wolffenbuttel KP; Arentshorst ME; Lodder P; Kok DJ
    J Urol; 2007 Oct; 178(4 Pt 2):1807-12. PubMed ID: 17707007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Population Pharmacokinetic Model of (R)- and (S-) Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers.
    Kretschmar M; Suleiman AA; Krause P; Albrecht U; Stein R; Rubenwolf P; Fuhr U; Taubert M
    J Clin Pharmacol; 2021 Jul; 61(7):961-971. PubMed ID: 33368382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of oxybutynin hydrochloride on isolated smooth muscles (ileum, urinary bladder and urethra)].
    Aida Y; Kaneko Y; Kasama T
    Nihon Yakurigaku Zasshi; 1986 Jun; 87(6):629-39. PubMed ID: 3744169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of intravesical and oral oxybutynin chloride.
    Massad CA; Kogan BA; Trigo-Rocha FE
    J Urol; 1992 Aug; 148(2 Pt 2):595-7. PubMed ID: 1640530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolterodine--a new bladder-selective antimuscarinic agent.
    Nilvebrant L; Andersson KE; Gillberg PG; Stahl M; Sparf B
    Eur J Pharmacol; 1997 May; 327(2-3):195-207. PubMed ID: 9200560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.